Search PubMed⌕ Search

Biomedical subjects

J Abele

Publications and source records attributed to J Abele.

8 recordsLinked to original sources
PubMed1982

Massive ovarian mucinous cystadenoma of low malignant potential.

Operative removal of an 80.3-kg ovarian mucinous cystadenoma of low malignant potential is described. The 30-year-old woman from whom the tumor was removed had many medical problems spanning several medical fields, including psychiatry and plastic surgery, as well as gynecology. The team approach to these problems is summarized in this case report.

Adult↗
PubMed1980

The role of hypertension in hemodialysis-associated atherosclerosis.

Atherosclerosis in 50 nondiabetic patients undergoing hemodialysis was assessed at the time of renal transplantation by intraoperative examination and histologic evaluation of the iliac vasculature. Patients were grouped accordingly: minimal (group 1), moderate (group 2) or severe (group 3) atherosclerosis. Sixty-two per cent of the patients had atherosclerosis, half of them with severe involvement. No sex differences were noted. There was a significant correlation between the patient's age and the degree of atherosclerosis (p less than 0.02). Thirty-five per cent of the patients under 30 years of age had atherosclerosis whereas similarly studied nonuremic control subjects had no atherosclerosis. Metabolic and lipid abnormalities, and duration of hemodialysis did not correlate with degree of atherosclerosis. Hypertension was present in 90 per cent of the patients in groups 2 and 3. When patients between the ages of 25 and 40 years were selected, atherosclerosis was present only in previously hypertensive patients (p less than 0.02). Atherosclerosis may not be accelerated by hemodialysis and may be prevented by more stringent control of hypertension in uremia.

Adolescent↗
PubMed1979

Aqueous primary standard for use in measuring cholesterol by the cholesterol oxidase method.

An aqueous primary standard is needed for measuring cholesterol by enzymatic procedures. Sodium deoxycholate solubilizes cholesterol in water. Crystalline cholesterol (1.00, 3.00, 4.00, and 5.00 g/L), added to a solution containing 150 g of this compound per liter of a 9 g/L saline solution, was measured by a cholesterol oxidase procedure, with a centrifugal analyzer. The solubilizer did not interfere. When compared to an isopropanol-based commercial cholesterol standard, the cholesterol standard in solubilizer showed excellent correlation (r = 0.986; m = 0.989). Day-to-day variation for the mixture during nine days was small (CV, 2.9% at 100 g/L, 3.7% at 3.00 g/L, and 1.8% at 4.00 g/L). Linearity was maintained up to 5.00 g/L. The cholesterol concentration in four reference sera so analyzed maintained CV's of less than 4%. The viscosity of the mixture was similar to that of serum. The standard mixtures, stored at room temperature for 360 days, remained stable. The solubilized cholesterol standard is shown to be suitable for use in the enzymatic procedure.

3-Hydroxysteroid Dehydrogenases↗
PubMedDate not supplied

Health reform and technology--what does it mean for us?

John Abele, Founder Chairman of Boston Scientific Corporation, spoke at AAMI's 30th Annual Meeting on 22 May in Anaheim, CA. His speech was part of AAMI's plenary session, "The Impact of a Reformed Health System on New Technology." After his speech, Abele joined three of AAMI's experts in a roundtable discussion on the topics he raised. See the BI&T Forum page 479 for their discussion. As a business entrepreneur and scientist, Abele is well versed in the topic of health reform and scientific advancements. He began his career with a degree in physics and philosophy, then moved into the health care field because of his fascination with medical devices and technologies. He has spent years working as an engineer, a salesperson, a general manager, and a partner in a research and development company. He was a cofounder of AAMI in 1965. Boston Scientific's roots trace back to 1969, when Abele joined with Itzhak Bentov to build a company around a steerable catheter. The associated technology became a platform for many types of tools that could be used as alternatives to surgery in most organs of the body. Today, with over 5,000 employees, 4,000 products, and a worldwide presence, the original objective of developing products and procedures that reduce risk, trauma, cost, and time still applies. Abele is the author of many papers and book chapters, and he has lectured extensively on the technology of various medical devices and technical, social, economic, and political trends affecting health care. His major interests are science education and the process by which new technology is invented, developed, and introduced to society. The following article is based on Abele's presentation.

Health Care Reform↗